A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Genes encoding components of the PI3K–AKT–mTOR signaling axis are frequently mutated in cancer, but few mutations have been characterized in MTOR, the gene encoding the mTOR kinase. Using publicly available tumor genome sequencing data, we generated a comprehensive catalog of mTOR pathway mutations...
Main Authors: | Grabiner, Brian C., Nardi, Valentina, Birsoy, Kivanc, Possemato, Richard, Shen, Kuang, Sinha, Sumi, Jordan, Alexander, Beck, Andrew H., Sabatini, David |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology |
Format: | Article |
Language: | en_US |
Published: |
American Association for Cancer Research
2015
|
Online Access: | http://hdl.handle.net/1721.1/96742 https://orcid.org/0000-0002-1446-7256 |
Similar Items
-
Structure of the human mTOR Complex I and its implications for rapamycin inhibition
by: Yip, Calvin K., et al.
Published: (2012) -
Rapamycin inhibits mTORC1, but not completely
by: Thoreen, Carson C, et al.
Published: (2012) -
A Different Way of Doing Things
by: Birsoy, Kıvanç, et al.
Published: (2018) -
mTOR Signaling in Growth Control and Disease
by: Laplante, Mathieu, et al.
Published: (2014) -
Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
by: Wagle, N., et al.
Published: (2015)